Tarini A. Gunawardena

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

OC43 clinical isolate spike proteins have distinct carbohydrate-binding properties.

OC43 clinical isolate spike proteins have distinct carbohydrate-binding properties.

Journal: Nature communications

Published: July 14, 2025

Deleterious effect of Pseudomonas aeruginosa on F508del-CFTR rescued by elexacaftor/tezacaftor/ivacaftor is clinical strain-dependent in patient-derived nasal cells.

Deleterious effect of Pseudomonas aeruginosa on F508del-CFTR rescued by elexacaftor/tezacaftor/ivacaftor is clinical strain-dependent in patient-derived nasal cells.

Journal: ERJ open research

Published: September 23, 2024

Pathogenesis and transmission of SARS-CoV-2 D614G, Alpha, Gamma, Delta, and Omicron variants in golden hamsters.

Pathogenesis and transmission of SARS-CoV-2 D614G, Alpha, Gamma, Delta, and Omicron variants in golden hamsters.

Journal: Npj viruses

Published: August 12, 2024

Relationship between theratyping in nasal epithelial cells and clinical outcomes in people with cystic fibrosis.

Relationship between theratyping in nasal epithelial cells and clinical outcomes in people with cystic fibrosis.

Journal: The European respiratory journal

Published: April 16, 2024

Primary Human Nasal Epithelial Cell Culture.

Primary Human Nasal Epithelial Cell Culture.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: October 19, 2023

Correlation of Electrophysiological and Fluorescence-Based Measurements of Modulator Efficacy in Nasal Epithelial Cultures Derived from People with Cystic Fibrosis.

Correlation of Electrophysiological and Fluorescence-Based Measurements of Modulator Efficacy in Nasal Epithelial Cultures Derived from People with Cystic Fibrosis.

Journal: Cells

Published: March 03, 2023

Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.

Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: January 06, 2023

Validating organoid-derived human intestinal monolayers for personalized therapy in cystic fibrosis.

Validating organoid-derived human intestinal monolayers for personalized therapy in cystic fibrosis.

Journal: Life science alliance

Published: November 26, 2022

Modulator Therapy in Cystic Fibrosis Patients with cis Variants in F508del Complex Allele: A Short-Term Observational Case Series.

Modulator Therapy in Cystic Fibrosis Patients with cis Variants in F508del Complex Allele: A Short-Term Observational Case Series.

Journal: Journal of personalized medicine

Published: June 08, 2022

A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients.

A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients.

Journal: Stem cell reports

Published: May 11, 2021

Preclinical Studies of a Rare CF-Causing Mutation in the Second Nucleotide Binding Domain (c.3700A>G) Show Robust Functional Rescue in Primary Nasal Cultures by Novel CFTR Modulators.

Preclinical Studies of a Rare CF-Causing Mutation in the Second Nucleotide Binding Domain (c.3700A>G) Show Robust Functional Rescue in Primary Nasal Cultures by Novel CFTR Modulators.

Journal: Journal of personalized medicine

Published: October 12, 2020

Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator.

Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator.

Journal: The European respiratory journal

Published: April 11, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026